NYSE:ZYME

Zymeworks Stock Insider Trading

etoro logo Buy ZYME
*Your capital is at risk
$24.35
+0.240 (+1.00%)
At Close: Jun 03, 2026

Zymeworks Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 51.85. In total, the insiders bought 4.91M and sold 187.93K ZYME shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 100 transactions)
51.85
Buy 4.91M shares
Sell 187.93K shares
90% Buy Activity
Strong Negative Correlation
Sell Signal Low Confidence
Jan 12, 2026

Analysis Breakdown:

  • Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 51.85.
  • Partially supported by a negative historical correlation.
  • Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date Type Person Role Amount
Jan 05, 2026
Buy
Common Stock
M-Exempt
Galbraith Kenneth
Chair & CEO
CEO / President 47 668
Value: $1.21M
Jan 05, 2026
Sell
Common Stock
S-Sale
Galbraith Kenneth
Chair & CEO
CEO / President 22 657
Value: $568.6K
Jan 05, 2026
Buy
Restricted Stock Unit
M-Exempt
Galbraith Kenneth
Chair & CEO
CEO / President 66 666
Value: $1.70M
Jan 05, 2026
Buy
Restricted Stock Unit
M-Exempt
Galbraith Kenneth
Chair & CEO
CEO / President 47 668
Value: $1.21M
Jan 05, 2026
Buy
Common Stock
M-Exempt
Moore Paul Andrew
Chief Scientific Officer
Officer 20 000
Value: $509.6K
Jan 05, 2026
Buy
Common Stock
M-Exempt
Moore Paul Andrew
Chief Scientific Officer
Officer 17 168
Value: $437.4K
Jan 05, 2026
Sell
Common Stock
S-Sale
Moore Paul Andrew
Chief Scientific Officer
Officer 10 821
Value: $271.6K
Jan 05, 2026
Sell
Common Stock
S-Sale
Moore Paul Andrew
Chief Scientific Officer
Officer 9 289
Value: $233.1K
Jan 05, 2026
Buy
Restricted Stock Unit
M-Exempt
Moore Paul Andrew
Chief Scientific Officer
Officer 20 000
Value: $509.6K
Jan 05, 2026
Buy
Restricted Stock Unit
M-Exempt
Moore Paul Andrew
Chief Scientific Officer
Officer 17 168
Value: $437.4K
Dec 22, 2025
Buy
Restricted Stock Unit
M-Exempt
Galbraith Kenneth
Chair & CEO
CEO / President 100 000
Value: $2.76M
Dec 22, 2025
Sell
Common Stock
S-Sale
Galbraith Kenneth
Chair & CEO
CEO / President 47 528
Value: $1.28M
Dec 22, 2025
Buy
Common Stock
M-Exempt
Galbraith Kenneth
Chair & CEO
CEO / President 100 000
Value: $2.76M
Aug 12, 2025
Buy
Common Stock
A-Award
Ciongoli Gregory Austin
Director
Director 415 000
Value: $4.99M
Aug 11, 2025
Buy
Stock Option (Right to Buy)
A-Award
Ciongoli Gregory Austin
Director
Director 62 000
Value: $771.3K
Aug 11, 2025
Buy
Stock Option (Right to Buy)
A-Award
Landry Robert E
Director
Director 62 000
Value: $771.3K
Aug 11, 2025
Buy
Stock Option (Right to Buy)
A-Award
Landry Robert E
Director
Director 62 000
Value: $771.3K
Aug 11, 2025
Buy
Stock Option (Right to Buy)
A-Award
Ciongoli Gregory Austin
Director
Director 62 000
Value: $771.3K
Aug 10, 2025
Buy
No securities are beneficially owned
Landry Robert E
Director
Director 0
Value: $0
Aug 10, 2025
Buy
Common Stock
Ciongoli Gregory Austin
Director
Director 0
Value: $0
Aug 10, 2025
Buy
Common Stock
Ciongoli Gregory Austin
Director
Director 0
Value: $0
Aug 10, 2025
Buy
No securities are beneficially owned
Ciongoli Gregory Austin
Director
Director 0
Value: $0
Aug 10, 2025
Buy
Common Stock
Ciongoli Gregory Austin
Director
Director 0
Value: $0
Aug 10, 2025
Buy
Common Stock
Ciongoli Gregory Austin
Director
Director 0
Value: $0
Aug 10, 2025
Buy
No securities are beneficially owned
Landry Robert E
Director
Director 0
Value: $0

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT ZYMEWORKS INC
Zymeworks
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 ...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE